Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
A patient taking part in this program will be provided with a 60mg dosage of BIA 28-6156. This will be taken orally once daily (OD) for the duration of the program, currently scheduled to run for 27 months.
Patients will visit the site approximately every 3 months for a drug re-supply. At these visits, the treating physician will reassess if the patient should continue with the treatment.
In case of tolerability concerns, the dose of BIA 28-6156 will be stopped per the treating physician's assessment.
The treating physician should discontinue treatment for the patient and/or withdraw the patient from this program if he/she believes that continuation would be detrimental to the patient's well-being.
Patients may voluntarily withdraw from treatment at any time, for any reason.
Study Type
Study Type
Expanded Access Type
Expanded Access Type
- Individual Patients: Allows a single patient, with a serious disease or condition who cannot participate in a clinical trial, access to a drug or biological product that has not been approved by the FDA. This category also includes access in an emergency situation.
- Intermediate-size Population: Allows more than one patient (but generally fewer patients than through a Treatment IND/Protocol) access to a drug or biological product that has not been approved by the FDA. This type of expanded access is used when multiple patients with the same disease or condition seek access to a specific drug or biological product that has not been approved by the FDA.
- Treatment IND/Protocol: Allows a large, widespread population access to a drug or biological product that has not been approved by the FDA. This type of expanded access can only be provided if the product is already being developed for marketing for the same use as the expanded access use.
- Treatment IND/Protocol
Contacts and Locations
Study Contact
Study Contact
- Name: Raquel Costa
- Phone Number: 00351229866100
- Email: raquel.costa@bial.com
Study Contact Backup
- Name: Miguel Fonseca
- Phone Number: 00351229866100
- Email: miguel.fonseca@bial.com
Study Locations
-
-
-
Bologna, Italy
- IRCCS Istituto Delle Scienze Neurologiche DI
-
Brescia, Italy, 25123
- Spedali Civilia di Brescia
-
Brindisi, Italy, 72100
- Ospedale Antonio Perrino
-
Milan, Italy, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Naples, Italy, 80138
- Universita degli Studi della Campania Luigi Vanvitelli - Clinica Neurologia I
-
Padova, Italy, 35128
- Universita Degli Studi Di Padova - Azienda Ospedaliera Di Padova - Clinica Neurologica
-
Roma, Italy, 163
- IRCSS San Raffaele Pisana
-
Salerno, Italy, 84125
- A.O.U. San Giovanni di Dio Ruggi d'Aragona Centro Parkinson- Piano Rialzato Corpo QT
-
-
-
-
-
Guimarães, Portugal, 4835-044
- Hospital Senhora da Oliveira de Guimaraes
-
-
-
-
-
Badalona, Spain, 08916
- Hospital Universitari Germans Trias i Pujol
-
Barakaldo, Spain, 48903
- Hospital Universitario Cruces
-
Barcelona, Spain, 08025
- Hospital de La Santa Creu i Sant Pau
-
Barcelona, Spain, 08035
- Hospital Vall D´Hebron
-
Madrid, Spain, 28034
- Hospital Ruber Internacional
-
Madrid, Spain, 28006
- Hospital Universitaio de La Princesa
-
Seville, Spain, 41013
- Hospital Universitario Virgen del Rocío
-
-
-
-
-
Dundee, United Kingdom
- NHS Tayside-Ninewells Hospital and Medical School
-
London, United Kingdom
- King's College London - David Goldberg Centre
-
Newcastle upon Tyne, United Kingdom
- The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital
-
Plymouth, United Kingdom
- University Hospitals Plymouth NHS Trust
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Barrow Neurological Institute
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Parkinson's Center and Movement Disorders of Boca Raton
-
Miami, Florida, United States, 33136
- University of Miami, Dept. of Neurology
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Kansas
-
Kansas City, Kansas, United States, 66103
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55427
- Park Nicollet Struther's Parkinson's Center (Struthers Parkinsons Center at HealthPartners)
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- MUSC
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt Medical Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- Intermountain Healthcare
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
Spokane, Washington, United States, 99202
- Inland Northwest Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A patient who completes Part B (Double Blind Treatment arm) of the ACTIVATE study supplied by BIAL R&D Investments, S.A., and falls within one week of completing the safety follow up visit from the ACTIVATE study.
- A patient is willing to provide written informed consent prior to initiating treatment, in accordance with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. A patient who, in the opinion of the treating physician will likely adhere to the program.
- A patient's treating physician believes the patient could benefit from treatment with BIA 28-6156.
- Patient has received approval from Supplier or its designee following the treating physician request submission.
- If a sexually active man or a woman of childbearing potential, the patient agrees to use highly effective birth control or to remain abstinent during the program and for 30 days after the last dose of BIA 28-6156. Acceptable (highly effective) methods of contraception for this study include hormonal contraceptives (combined oral contraceptive, patch, vaginal ring, injectable, or implant); intrauterine device or system; complete abstinence from sexual intercourse if this is the patient's usual and preferred lifestyle; or sexual partner with surgical sterilization (e.g., tubal ligation, hysterectomy and/or bilateral oophorectomy.
Exclusion Criteria:
- A patient that has previously discontinued for any reason from the BIA 28-6156-201 clinical study.
- A patient who is pregnant, may be pregnant, lactating, or planning to be pregnant.
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BIA 28-6156 CUP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.